Traders should monitor for Celularity's plan to regain Nasdaq compliance, including any filing of delinquent 10-Qs. The stock is at high risk of delisting if the company fails to submit a compliance plan or meet deadlines, which could lead to a significant price decline. Avoid long positions until compliance is restored.
Price Chart
Executive Summary
Celularity Inc. disclosed it received a Nasdaq delinquency notice for failing to file its Q1 and Q2 2026 quarterly reports, indicating ongoing compliance issues with listing rules. The company also reported a Q4 2025 EPS of -$0.85, which beat a consensus estimate of N/A, but the filing delinquency and lack of current financials overshadow any earnings beat. This is a bearish signal for a micro-cap biotech with a $22M market cap, as the Nasdaq non-compliance threatens listing stability and investor confidence.
Key Financial Metrics
Key Facts
- Celularity received a Nasdaq delinquency notice on August 21, 2026 for not filing its Q1 and Q2 2026 Form 10-Qs.
- The company remains delinquent in filing its Quarterly Report for the period ended March 31, 2026.
- Nasdaq Listing Rule 5250(c)(1) requires timely filing of all periodic financial reports.
- Reported Q4 2025 EPS of -$0.85, beating a consensus estimate of N/A.
- Market cap is approximately $22M, making the stock highly sensitive to compliance news.
Financial Impact
Nasdaq non-compliance could lead to delisting, severely impacting stock liquidity and valuation for a $22M market cap company.
Risk Factors
- Potential delisting from Nasdaq if delinquent filings are not resolved.
- Lack of current financial data increases uncertainty and risk of adverse surprises.
- Micro-cap status amplifies volatility and downside risk on negative news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3351048 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 10-K/A | $1.26 | awaiting T+60 | — | $0.7500 (+40.48%) |
Sep 30, 2026 27d ago | Press Release | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 29, 2026 28d ago | 8-K | $1.35 | awaiting T+60 | — | $0.7500 (−44.44%) |
Sep 28, 2026 29d ago | SC 13D/A | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 28, 2026 29d ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (+46.43%) |
Sep 24, 2026 4w ago | Press Release | $1.32 | awaiting T+60 | — | $0.7500 (−43.18%) |
Sep 14, 2026 6w ago | 8-K | $1.40 | awaiting T+60 | — | $0.7500 (−46.43%) |
Aug 25, 2026 9w ago | Press Release | $0.8804 | awaiting T+60 | — | $0.7500 (+14.81%) |
Aug 7, 2026 11w ago | 8-K | $0.6866 | awaiting T+60 | — | $0.7500 (−9.23%) |
Jun 30, 2026 17w ago | 8-K | $0.5979 $1.15 | ▼ −92.34% | ▼ −88.78% | $0.7500 (−25.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers